Public Offering

  • Customers Bancorp, Inc. Announces Pricing of Common Stock Offering

    On September 3, 2025, Customers Bancorp (CUBI) announced the pricing of a public offering of 2,189,781 shares of voting common stock at $68.50 per share, expected to generate $150 million. Underwriters have an option to purchase additional shares. Net proceeds will be used for general corporate purposes, including organic growth, debt refinancing, share repurchases, preferred stock redemption, capital investments, and potential acquisitions. The offering is expected to close around September 5, 2025. This move strengthens the bank’s balance sheet amid a complex economic environment.

    2025年9月3日
  • AGNC Investment Corp. Prices Public Offering of Depositary Shares

    AGNC Investment Corp. (Nasdaq: AGNC) announced the pricing of a public offering of 12,000,000 depositary shares representing preferred stock, with gross proceeds of $300 million. Underwriters have a 30-day option for additional shares. Listing on Nasdaq is planned under “AGNCZ,” with closing expected around September 10, 2025. Proceeds will be invested in a diversified portfolio including Agency securities and credit risk transfer securities. Managed by a consortium of financial institutions, the offering is under an existing shelf registration statement. The strategy aims to bolster capital amid volatile market conditions.

    2025年9月3日
  • Thumzup Media Updates Terms of Proposed Public Offering

    Thumzup Media (TZUP) updated its public offering to include pre-funded warrants for common stock. The funds will target cryptocurrencies, mining equipment, working capital, and general corporate purposes. The offering’s completion is subject to market conditions. Thumzup’s platform pays users for sharing branded content and is developing an AI Lifestyle Agent Marketplace. The announcement contains forward-looking statements subject to risks. Investors should carefully review SEC filings and the prospectus before investing.

    2025年8月9日
  • Southwest Gas Holdings Announces Pricing of Centuri Holdings, Inc. Secondary Offering

    Southwest Gas Holdings is reducing its stake in Centuri Holdings through a secondary public offering of 15 million shares at $19.50 each. Underwriters have an option to purchase an additional 2.25 million shares. Carl Icahn’s affiliates will acquire 1,573,500 shares in a concurrent private placement at the same price. J.P. Morgan, Wells Fargo Securities, BofA Securities, and Moelis & Company are lead book-running managers. The offering, expected to close on August 11th, marks Southwest Gas’s strategic realignment and could signal further changes in its Centuri investment.

    2025年8月7日
  • Prime Medicine Announces Pricing of Public Offering

    Prime Medicine (PRME) announced a public offering of 38 million shares at $3.30 per share, expecting $125.4 million in gross proceeds. The Cystic Fibrosis Foundation will purchase 1.8 million shares without underwriter commissions. Underwriters have an option to purchase 5.7 million additional shares. The offering, managed by TD Cowen and BMO Capital Markets, is set to close around August 1, 2025. Proceeds will bolster Prime Medicine’s gene therapy pipeline advancement. The offering may cause dilution for existing shareholders.

    2025年7月30日
  • SoFi Announces Pricing of Common Stock Public Offering

    SoFi Technologies (NASDAQ: SOFI) has priced its public offering of 71,942,450 shares at $20.85 per share, generating approximately $1.5 billion in gross proceeds. Underwriters have a 30-day option to purchase an additional 10,791,367 shares. The offering is expected to close on July 31, 2025, and SoFi intends to use the proceeds for general corporate purposes, including working capital and strategic opportunities. Goldman Sachs, Citigroup, and Mizuho Securities are acting as underwriters. SoFi offers a suite of digital financial services to over 11.7 million members.

    2025年7月29日
  • Absci Announces Pricing of Public Offering

    Absci (ABSI) announced the pricing of its public offering of 16,670,000 shares at $3.00 per share, expecting gross proceeds of $50 million. Underwriters have a 30-day option to purchase an additional 2,500,500 shares. Absci will use the funds for program advancements, platform investment, and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are managing the offering, expected to close around July 25, 2025.

    2025年7月24日
  • DEFSEC Technologies Prices CAD$6.8 Million Public Offering

    DEFSEC Technologies Inc. (DFSC) announced the pricing of a CAD$6.8 million public offering consisting of units with common shares (or pre-funded warrants) and warrants. Each unit, priced at CAD$8.955, includes one share/warrant, with warrants exercisable at CAD$10.52 within five years. H.C. Wainwright & Co. is the placement agent. Closing is expected around July 25, 2025. Net proceeds will be used for working capital and general corporate purposes. The offering, while injecting capital, introduces potential dilution for existing shareholders.

    2025年7月24日
  • Karman Space & Defense Announces Pricing of Upsized Public Offering

    Karman Space & Defense (KRMN) announced the pricing of a public offering of 21 million shares at $49 per share, offered by existing stockholders. Underwriters, led by Citigroup and Evercore ISI, have a 30-day option to purchase an additional 3.15 million shares. Karman will not receive any proceeds from the offering, which is expected to close on July 25th, 2025. The SEC approved the registration statement on July 23, 2025. Karman provides critical systems for the space and defense industries.

    2025年7月23日
  • Tharimmune Announces $1.74 Million Registered Direct Offering of Common Stock and Warrants

    Tharimmune (THAR) announced a $1.74 million registered direct offering consisting of common stock and warrants. Units are priced at $1.786, including one share or pre-funded warrant and a common warrant. President Street Global is the placement agent. Proceeds will fund working capital and general corporate purposes. The offering is expected to close around July 25, 2025. This funding aims to support Tharimmune’s work in immunology and inflammation therapies, including their clinical asset, TH104.

    2025年7月23日